<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="9168">Rapamycin</z:chebi>, an mTOR inhibitor and <z:chebi fb="1" ids="35705">immunosuppressive agent</z:chebi> in clinic, has protective effects on traumatic brain injury and <z:hpo ids='HP_0002180'>neurodegenerative diseases</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>But, its effects on transient focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>/reperfusion disease are not very clear </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we examined the effects of <z:chebi fb="0" ids="9168">rapamycin</z:chebi> preconditioning on mice treated with middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>/reperfusion operation (MCAO/R) </plain></SENT>
<SENT sid="3" pm="."><plain>We found that the <z:chebi fb="0" ids="9168">rapamycin</z:chebi> preconditioning by intrahippocampal injection 20 hr before MCAO/R significantly improved the survival rate and longevity of mice </plain></SENT>
<SENT sid="4" pm="."><plain>It also decreased the neurological deficit score, infracted areas and <z:hpo ids='HP_0002181'>brain edema</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, <z:chebi fb="0" ids="9168">rapamycin</z:chebi> preconditioning decreased the production of NF-κB, TNF-α, and Bax, but not Bcl-2, an antiapoptotic protein in the ischemic area </plain></SENT>
<SENT sid="6" pm="."><plain>From these results, we may conclude that <z:chebi fb="0" ids="9168">rapamycin</z:chebi> preconditioning attenuate transient focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>/reperfusion injury and inhibits <z:mpath ids='MPATH_3'>apoptosis</z:mpath> induced by MCAO/R in mice </plain></SENT>
</text></document>